Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy

키워드

참고문헌 (82)

1. Hua Y, "Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model", Genes Dev, 24, pp.1634~1644 (2010)
2. Singh NK, "Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron", Mol Cell Biol, 26, pp.1333~1346 (2006)
3. Wan L, "The survival of motor neurons protein determines the capacity for snRNP assembly : biochemical deficiency in spinal muscular atrophy", Mol Cell Biol, 25, pp.5543~5551 (2005)
4. Hua Y, "Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon", PLoS Biol, 5, pp.e73~ (2007)
5. Kashima T, "A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy", Nat Genet, 34, pp.460~463 (2003)
6. Cartegni L, "Disruption of an SF2", ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1, 2002, pp.30, 377~384
7. Lunn MR, "Spinal muscular atrophy", Lancet, 371, pp.2120~2133 (2008)
8. Foust KD, "Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN", Nat Biotechnol, 28, pp.271~274 (2010)
9. Coady TH, "Restoration of SMN function : delivery of a trans-splicing RNA re-directs SMN2 premRNA splicing", Mol Ther, 15, pp.1471~1478 (2007)
10. Madocsai C, "Correction of SMN2Pre-mRNA splicing by antisense U7 small nuclear RNAs", Mol Ther, 12, pp.1013~1022 (2005)
11. Khorkova O, "Oligonucleotide therapies for disorders of the nervous system", Nat Biotechnol, 35, pp.249~263 (2017)
12. Farr SA, "Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576(AβPPswe)mice", J Alzheimers Dis, 40, pp.1005~1016 (2014)
13. Juliano RL, "The delivery of therapeutic oligonucleotides", Nucleic Acids Res, 44, pp.6518~6548 (2016)
14. Eckstein F, "Nucleoside phosphorothioates", J Am Chem Soc, 92, pp.4718~4723 (1970)
15. Bobst AM, "Effect of the methylation of the 2’-hydroxyl groups in polyadenylic acid on its structure in weakly acidic and neutral solutions and on its capability to form ordered complexes with polyuridylic acid", J Mol Biol, 46, pp.221~234 (1969)
16. Evers MM, "Antisense oligonucleotides in therapy for neurodegenerative disorders", Adv Drug Deliv Rev, 87, pp.90~103 (2015)
17. Hua Y, "Antisense masking of an hnRNP A1", A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice, 2008, pp.82, 834~848
18. Rigo F, "Antisense-based therapy for the treatment of spinal muscular atrophy", J Cell Biol, 199, pp.21~25 (2012)
19. Juliano RL, "Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides", Bioconjug Chem, 23, pp.147~157 (2012)
20. Koller E, "Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes", Nucleic Acids Res, 39, pp.4795~4807 (2011)
21. Wagenaar TR, "Identification of the endosomal sorting complex required for transport-I(ESCRT-I)as an important modulator of anti-miR uptake by cancer cells", Nucleic Acids Res, 43, pp.1204~1215 (2015)
22. Liang XH, "Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2’-modifications and enhances antisense activity", Nucleic Acids Res, 44, pp.3892~3907 (2016)
23. Shemesh CS, "Pharmacokinetic and pharmacodynamic investigations of ION-353382, a model antisense oligonucleotide : using alpha-2-macroglobulin and murinoglobulin double-knockout mice", Nucleic Acid Ther, 26, pp.223~235 (2016)
24. Shen W, "Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures", Nucleic Acids Res, 42, pp.8648~8662 (2014)
25. Liang XH, "TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells", Nucleic Acids Res, 42, pp.7819~7832 (2014)
26. Liang XH, "Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages", Nucleic Acids Res, 43, pp.2927~2945 (2015)
27. Ezzat K, "Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides", FASEB J, 26, pp.1172~1180 (2012)
28. Ugarte-Uribe B, "Synthesis, cell-surface binding, and cellular uptake of fluorescently labeled glucose-DNA conjugates with different carbohydrate presentation", Bioconjug Chem, 21, pp.1280~1287 (2010)
29. Cheng CJ, "Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides", Biomaterials, 32, pp.6194~6203 (2011)
30. Alam MR, "Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis", Nucleic Acids Res, 36, pp.2764~2776 (2008)
31. Juliano RL, "Receptors, endocytosis, and trafficking : the biological basis of targeted delivery of antisense and siRNA oligonucleotides", J Drug Target, 21, pp.27~43 (2013)
32. Juliano RL, "Cellular uptake and intracellular trafficking of oligonucleotides : implications for oligonucleotide pharmacology", Nucleic Acid Ther, 24, pp.101~113 (2014)
33. Sahay G, "Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling", Nat Biotechnol, 31, pp.653~658 (2013)
34. Ming X, "Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor", Nucleic Acids Res, 38, pp.6567~6576 (2010)
35. Miller CM, "Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides(ASOs)in the liver", Nucleic Acids Res, 44, pp.2782~2794 (2016)
36. Kortylewski M, "In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses", Nat Biotechnol, 27, pp.925~932 (2009)
37. Shi F, "Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator of fibronectin turnover", J Cell Sci, 121(Pt 14), pp.2360~2371 (2008)
38. Juliano RL, "Cellular uptake and intracellular trafficking of oligonucleotides", Adv Drug Deliv Rev, 87, pp.35~45 (2015)
39. Reyes-Reyes EM, "A new paradigm for aptamer therapeutic AS1411 action : uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism", Cancer Res, 70, pp.8617~8629 (2010)
40. Ezzat K, "Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides", Nano Lett, 15, pp.4364~4373 (2015)
41. Kotula JW, "Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells", Nucleic Acid Ther, 22, pp.187~195 (2012)
42. Wang S, "Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides", Nucleic Acids Res, 44, pp.7314~7330 (2016)
43. Prakash TP, "Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice", Nucleic Acids Res, 42, pp.8796~8807 (2014)
44. Vickers TA, "Development of a quantitative BRET affinity assay for nucleic acid-protein interactions", PLoS One, 11, pp.e0161930~ (2016)
45. Castanotto D, "A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells", Nucleic Acids Res, 43, pp.9350~9361 (2015)
46. Lorenz P, "Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies", Mol Biol Cell, 9, pp.1007~1023 (1998)
47. Kubo T, "Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation", Org Biomol Chem, 3, pp.3257~3259 (2005)
48. Marcusson EG, "Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus", Nucleic Acids Res, 26, pp.2016~2023 (1998)
49. Zelphati O, "Mechanism of oligonucleotide release from cationic liposomes", Proc Natl Acad Sci U S A, 93, pp.11493~11498 (1996)
50. Naganuma T, "Paraspeckle formation during the biogenesis of long non-coding RNAs", RNA Biol, 10, pp.456~461 (2013)
51. Lorenz P, "Nucleocytoplasmic shuttling : a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides", Nucleic Acids Res, 28, pp.582~592 (2000)
52. Doherty GJ, "Mechanisms of endocytosis", Annu Rev Biochem, 78, pp.857~902 (2009)
53. Stein CA, "Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents", Nucleic Acids Res, 38, pp.e3~ (2010)
54. Torres AG, "Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids(PNA)and phosphorothioate locked nucleic acid(LNA)", 2'-Omethyl(OMe)mixmer anti-miRs in the absence of transfection agents, 2011, pp.2, 71~78
55. Smith RA, "Antisense oligonucleotide therapy for neurodegenerative disease", J Clin Invest, 116, pp.2290~2296 (2006)
56. Wahlestedt C, "Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions", Nature, 363, pp.260~263 (1993)
57. Wahlestedt C, "Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides", Science, 259, pp.528~531 (1993)
58. Wahlestedt C, "Antisense oligonucleotide strategies in neuropharmacology", Trends Pharmacol Sci, 15, pp.42~46 (1994)
59. Standifer KM, "Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor", Neuron, 12, pp.805~810 (1994)
60. Pechmann A, "Single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1", Eur J Paediatr Neurol, 22, pp.122~127 (2018)
61. Zanetta C, "Molecular therapeutic strategies for spinal muscular atrophies : current and future clinical trials", Clin Ther, 36, pp.128~140 (2014)
62. Passini MA, "Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy", Sci Transl Med, 3, pp.72ra18~ (2011)
63. Geary RS, "Antisense oligonucleotide pharmacokinetics and metabolism", Expert Opin Drug Metab Toxicol, 5, pp.381~391 (2009)
64. Rigo F, "Pharmacology of a central nervous system delivered 2'-O-methoxyethylmodified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates", J Pharmacol Exp Ther, 350, pp.46~55 (2014)
65. Heemskerk H, "Preclinical PK and PD studies on 2'-O-methylphosphorothioate RNA antisense oligonucleotides in the mdx mouse model", Mol Ther, 18, pp.1210~1217 (2010)
66. Verhaart IE, "Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice", Nucleic Acid Ther, 23, pp.228~237 (2013)
67. Kordasiewicz HB, "Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis", Neuron, 74, pp.1031~1044 (2012)
68. Geary RS, "Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides", Adv Drug Deliv Rev, 87, pp.46~51 (2015)
69. Chiriboga CA, "Results from a phase 1 study of nusinersen(ISISSMN(Rx))in children with spinal muscular atrophy", Neurology, 86, pp.890~897 (2016)
70. Haché M, "Intrathecal injections in children with spinal muscular atrophy : nusinersen clinical trial experience", J Child Neurol, 31, pp.899~906 (2016)
71. Engelhardt JA, "Comparative renal toxicopathology of antisense oligonucleotides", Nucleic Acid Ther, 26, pp.199~209 (2016)
72. Matsuzawa J, "Age-related volumetric changes of brain gray and white matter in healthy infants and children", Cereb Cortex, 11, pp.335~342 (2001)
73. Finkel RS, "Treatment of infantile-onset spinal muscular atrophy with nusinersen : a phase 2, open-label, dose-escalation study", Lancet, 388, pp.3017~3026 (2016)
74. Frisone MF, "Prognostic value of the neurologic optimality score at 9 and 18 months in preterm infants born before 31 weeks’ gestation", J Pediatr, 140, pp.57~60 (2002)
75. Glanzman AM, "The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders(CHOP INTEND) : test development and reliability", Neuromuscul Disord, 20, pp.155~161 (2010)
76. Yu RZ, "Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma", Anal Biochem, 304, pp.19~25 (2002)
77. Finkel RS, "Nusinersen versus sham control in infantile-onset spinal muscular atrophy", N Engl J Med, 377, pp.1723~1732 (2017)
78. Mercuri E, "Nusinersen versus sham control in later-onset spinal muscular atrophy", N Engl J Med, 378, pp.625~635 (2018)
79. Glanzman AM, "Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III", J Child Neurol, 26, pp.1499~1507 (2011)
80. O’Hagen JM, "An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients", Neuromuscul Disord, 17, pp.693~697 (2007)
81. Ebinger F, "Headache and backache after lumbar puncture in children and adolescents : a prospective study", Pediatrics, 113, pp.1588~1592 (2004)
82. Morgenlander JC, "Lumbar puncture and CSF examination. Answers to three commonly asked questions", Postgrad Med, 95, pp.125~128 (1994)

관련 논문AI추천